Whitehawk (WHWK) Chief Technical Ops Officer Bryan Ball Receives Awards

What Happened
Bryan Ball, Chief Technical Operations Officer of Whitehawk Therapeutics, was granted two derivative awards on Sept 15, 2026 — each for 91,633 units, for a combined total of 183,266 units. Each award was reported at $0.00 (no cash paid). The filing indicates these awards include restricted stock units (RSUs) and an option-like award, each subject to vesting conditions rather than immediate ownership of shares.

Key Details

• Transaction date: 2026-09-15. Report filed the same day. Report lists price $0.00 for both awards.
• Awards: 91,633 units + 91,633 units = 183,266 total derivative units. Each RSU represents a contingent right to one share.
• Vesting: Vesting Commencement Date is Sept 15, 2026. One award vests 25% after one year and then monthly (1/48th) thereafter to fully vest in four years; the other award vests 25% each year over four years. Vesting is contingent on continued service.
• Shares owned after transaction: Not specified in the public filing.
• Filing timeliness: Filing reflects the same period date (no late filing flag noted).
• Remarks: Listed role — Chief Technical Operations Officer.

Context
These are grants/awards (derivative awards/RSUs and an option-like award), not open-market purchases or sales. No shares were sold or purchased for cash at the time of grant; the awards vest over time and convert to actual shares only if vesting conditions are met. Grants are common executive compensation and do not by themselves indicate intent to buy or sell stock.